 |
|
Recombinant Factor VIIa and Thromboembolic Events
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr O’Connell and colleagues1 reviewed thromboembolic complications of recombinant human coagulation factor VIIa (rFVIIa) as reported to the US Food and Drug Administration (FDA) MEDWATCH database. As with any medication, rFVIIa has both positive and negative effects; therefore, risks and benefits must be considered before administering the drug. In our trauma practice, we cannot know which of our patients with life-threatening hemorrhage are also at risk for ischemic stroke, myocardial infarction, or other thrombotic complications. We are cautious with rFVIIa use in the presence of arterial injury and will not use it in patients undergoing extracorporeal circulatory support. However, some patients have dilutional coagulopathy severe enough to warrant the use of almost any therapy to salvage them from hemorrhagic shock, regardless of risk.2 A recent randomized, placebo-controlled, double-blind trial of the use of rFVIIa in patients with trauma did not find an increased risk . . . [Full Text of this Article]
Richard P. Dutton, MD, MBA
rdutton@umaryland.edu
Deborah M. Stein, MD, MPH;
John R. Hess, MD, MPH;
Thomas M. Scalea, MD
The R. Adams Cowley Shock Trauma Center
University of Maryland Medical System
Baltimore
RELATED ARTICLES
Recombinant Factor VIIa and Thromboembolic Events—Reply
Kathryn A. O’Connell, Robert P. Wise, Jay N. Lozier, and M. Miles Braun
JAMA. 2006;296(1):44.
EXTRACT
| FULL TEXT
Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa
Kathryn A. O’Connell, Jennifer J. Wood, Robert P. Wise, Jay N. Lozier, and M. Miles Braun
JAMA. 2006;295(3):293-298.
ABSTRACT
| FULL TEXT
|
